These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

80 related articles for article (PubMed ID: 1286155)

  • 21. Platelet-activating factor stimulates phosphoinositide turnover in neurohybrid NCB-20 cells: involvement of pertussis toxin-sensitive guanine nucleotide-binding proteins and inhibition by protein kinase C.
    Yue TL; Stadel JM; Sarau HM; Friedman E; Gu JL; Powers DA; Gleason MM; Feuerstein G; Wang HY
    Mol Pharmacol; 1992 Feb; 41(2):281-9. PubMed ID: 1311408
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Mechanisms of drug inhibition of signalling molecules.
    Sebolt-Leopold JS; English JM
    Nature; 2006 May; 441(7092):457-62. PubMed ID: 16724058
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Targeting RAS signalling pathways in cancer therapy.
    Downward J
    Nat Rev Cancer; 2003 Jan; 3(1):11-22. PubMed ID: 12509763
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Aqueous humour- and growth factor-induced lens cell proliferation is dependent on MAPK/ERK1/2 and Akt/PI3-K signalling.
    Iyengar L; Patkunanathan B; Lynch OT; McAvoy JW; Rasko JE; Lovicu FJ
    Exp Eye Res; 2006 Sep; 83(3):667-78. PubMed ID: 16684521
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Hexa-, hepta- and nonaprenylhydroquinones isolated from marine sponges Sarcotragus muscarum and Ircinia fasciculata inhibit NF-kappaB signalling in H4IIE cells.
    Wätjen W; Putz A; Chovolou Y; Kampkötter A; Totzke F; Kubbutat MH; Proksch P; Konuklugil B
    J Pharm Pharmacol; 2009 Jul; 61(7):919-24. PubMed ID: 19589234
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Resistance to epidermal growth factor receptor-targeted therapy.
    Morgillo F; Lee HY
    Drug Resist Updat; 2005 Oct; 8(5):298-310. PubMed ID: 16172017
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Signalling targets for anticancer drug development.
    Powis G
    Trends Pharmacol Sci; 1991 May; 12(5):188-94. PubMed ID: 1862534
    [TBL] [Abstract][Full Text] [Related]  

  • 28. D-3-deoxy-3-substituted myo-inositol analogues as inhibitors of cell growth.
    Powis G; Aksoy IA; Melder DC; Aksoy S; Eichinger H; Fauq AH; Kozikowski AP
    Cancer Chemother Pharmacol; 1991; 29(2):95-104. PubMed ID: 1760864
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Inhibitors of phospholipid intracellular signaling as antiproliferative agents.
    Powis G; Hill SR; Frew TJ; Sherrill KW
    Med Res Rev; 1995 Mar; 15(2):121-38. PubMed ID: 7739293
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The cell membrane and cell signals: new targets for novel anticancer drugs.
    Workman P
    Ann Oncol; 1990; 1(2):100-11. PubMed ID: 1706612
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Glycosyl-phosphatidylinositol: a novel mechanism of signal transduction. Workshop on Role of Glycosyl-phosphatidylinositol in Cell Signalling, sponsored by Fundación Juan March, Madrid, Spain October 21-23, 1991.
    Mérida I
    New Biol; 1992 Mar; 4(3):207-11. PubMed ID: 1349821
    [No Abstract]   [Full Text] [Related]  

  • 32. Recent advances in the development of anticancer drugs that act against signalling pathways.
    Powis G
    Tumori; 1994 Apr; 80(2):69-87. PubMed ID: 8016910
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Inhibition of cell signalling pathways.
    Langdon SP; Smyth JF
    Cancer Treat Rev; 1995 Jan; 21(1):65-89. PubMed ID: 7859227
    [No Abstract]   [Full Text] [Related]  

  • 34. Signal transduction pathways: new targets in oncology.
    Sweeb RK; Beijnen JH
    Pharm World Sci; 1993 Dec; 15(6):233-42. PubMed ID: 8298582
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Detection of molecular targets on the phosphatidylinositol signaling pathway of Leishmania spp. through bioinformatics tools and mathematical modeling].
    Velásquez V; Ochoa R; Muskus C
    Biomedica; 2015; 35(2):235-46. PubMed ID: 26535546
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Therapeutic resistance in breast cancer: Impact of growth factor signalling pathways and implications for future treatment. Proceedings of the 1st Tenovus/AstraZeneca workshop, 3-4 February 2005, Cardiff, United Kingdom.
    Endocr Relat Cancer; 2005 Jul; 12 Suppl 1():S1-199. PubMed ID: 16281359
    [No Abstract]   [Full Text] [Related]  

  • 37. Inositol lipid-mediated cellular signalling.
    Potter BV; Gigg R
    Carbohydr Res; 1992 Oct; 234():xi-xxi. PubMed ID: 1468076
    [No Abstract]   [Full Text] [Related]  

  • 38. Cell-signaling targets for antitumour drug development.
    Brunton VG; Workman P
    Cancer Chemother Pharmacol; 1993; 32(1):1-19. PubMed ID: 8384936
    [No Abstract]   [Full Text] [Related]  

  • 39. Anticancer drugs acting against signaling pathways.
    Powis G
    Curr Opin Oncol; 1995 Nov; 7(6):554-9. PubMed ID: 8547405
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Inositide-Dependent Nuclear Signalling in Health and Disease.
    Follo MY; Ratti S; Manzoli L; Ramazzotti G; Faenza I; Fiume R; Mongiorgi S; Suh PG; McCubrey JA; Cocco L
    Handb Exp Pharmacol; 2020; 259():291-308. PubMed ID: 31889219
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.